Table 4.
Subjective Cognitive Decline | Slow Gait | Motor Cognitive Risk Syndrome | |||||||
---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | |
GDF-15 | 1.00 (0.99–1.01) |
1.00 (0.98–1.02) |
1.00 (0.97–1.03) |
1.01 (1.00–1.02) |
1.01 (0.99–1.02) |
1.01 (0.99–1.03) |
1.01
(1.00–1.02) |
1.01 (0.99–1.03) |
1.02 (0.99–1.04) |
IL-6 | 1.23 (0.80–1.87) |
0.88 (0.36–2.10) |
0.69 (0.22–2.16) |
1.26 (0.86–1.85) |
0.58 (0.23–1.42) |
0.19 (0.04–1.08) |
1.19 (0.74–1.90) |
0.79 (0.33–1.91) |
0.57 (0.11–2.87) |
IL-10 | 1.02 (0.95–1.09) |
1.06 (0.93–1.20) |
1.03 (0.89–1.18) |
1.02 (0.96–1.09) |
1.07 (0.94–1.21) |
1.04 (0.91–1.20) |
0.87 (0.53–1.44) |
0.68 (0.27–1.75) |
0.22
(0.05–0.98) |
PRGN | 0.99 (0.96–1.04) |
0.96 (0.88–1.04) |
0.96 (0.88–1.05) |
0.99 (0.95–1.03) |
0.96 (0.90–1.02) |
0.96 (0.89–1.04) |
0.99 (0.94–1.04) |
0.97 (0.90–1.04) |
0.99 (0.91–1.09) |
TNF-α | 0.97 (0.80–1.18) |
0.72 (0.41–1.26) |
0.87 (0.45–1.69) |
1.09 (0.94–1.28) |
0.99 (0.73–1.35) |
1.23 (0.79–1.93) |
1.23
(1.04–1.46) |
1.37
(1.01–1.87) |
1.55 (0.99–2.43) |
IL-10/TNF-α | 0.98 (0.95–1.01) |
0.99 (0.98–1.08) |
0.99 (0.97–1.01) |
0.99 (0.95–1.01) |
0.99 (0.98–1.04) |
0.99 (0.98–1.04) |
0.98
(0.97–0.99) |
0.98
(0.97–0.99) |
0.98
(0.97–0.99) |
PRGN/ TNF-α |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
0.98
(0.92–0.99) |
0.98
(0.96–0.99) |
1.00 (0.99–1.00) |
Reference group: Healthy; Values presented as Odds Ratio (95% Confidence Interval); Bold indicates significance (p < 0.05); GDF-15: Growth Differentiation Factor-15; IL6, Interleukin 6; IL-10: Interleukin 10; TNF-α: Tumor Necrosis Factor Alpha; PRGN: Progranulin. Model 1: Unadjusted. Model 2: Adjusted for age, gender, ethnicity, education years, hypertension, hyperlipidemia, diabetes, polypharmacy, nutritional status, physical activity and sarcopenia. Model 3: Adjusted for Model 2 and body fat percentage.